| abstract |
Disclosed is the use of an endothelial progenitor cell contacted with an immunomodulatory compound selected from: 1,3-dioxi-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 2-amino-N-(2-(3-methyl-2,6-dioxopiperidin-3yl)-1,3-dioxoisoindolin-4-yl)acetamide hydrochloride; a compound of formula (I); and a compound of formula (II); wherein the substituents are as defined herein or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in the manufacture of a composition for treating, managing or preventing a cardiovascular disorder associated with endothelial dysfunction. Also disclosed is the use of a compound as defined above, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in the manufacture of a composition for treating, managing or preventing a cardiovascular disorder associated with endothelial dysfunction, provided said disorder is not shock, congestive heart failure or pulmonary hypertension. |